Dmitrij Hristodorov

About Dmitrij Hristodorov

Dmitrij Hristodorov is a director at Memento Medicines.

Form D filings also name Dmitrij Hristodorov as a director at Progentos Therapeutics.

Dmitrij Hristodorov first appears on SEC filings in 2024.

Experience

This experience comes from Dmitrij Hristodorov's profile and from SEC filings. For roles taken from filings, the years are when the filings name Dmitrij Hristodorov in the role, so the role may have started earlier or lasted longer.

Memento Medicines, Inc. Current

Director

2026 – Present · Boston, MA

Develops antibody therapies for people with retinal diseases.

MT

Mosanna Therapeutics Current

Board Member

2025 – Present

PT

Progentos Therapeutics, Inc. Current

Director

2024 – Present · Watertown, MA

BT

Beacon Therapeutics Current

Board Member

2024 – Present

AB

AAVantgarde Bio Current

Board Member

2023 – Present

KY

Kynexis Current

Board Member

2022 – Present

ST

Seamless Therapeutics Current

Board Member

2022 – Present

CT

Complement Therapeutics Current

Board Member

2022 – Present

RT

RyCarma Therapeutics Current

Board Member

2021 – Present

FO

Forbion Current

General Partner

2020 – Present

RB

Rampart Bioscience

Board Member

2023 – 2025

OX

Oxular

Board Member

2021 – 2024

VE

VectorY

Board Observer

2020 – 2023

GT

Gyroscope Therapeutics

Board Observer

2021 – 2022

BP

Bayer Pharmaceuticals

Senior Director, Global Business Development & Licensing (2013 – 2020)

Director, Early Licensing, Global Business Development (2016 – 2018)

2013 – 2020

AC

antibodies-online.com

Data Management

2012 – 2013

FI

Fraunhofer IME

Research Scientist (PostDoc)

2011 – 2013

BH

Bayer HealthCare

Master Student

2010 – 2011

FC

Fraunhofer CMB

Bachelor Student

2009

Key Colleagues at Startups

The people Dmitrij Hristodorov works with at each company, as listed on that company's latest Form D.

Sources

1. SECMemento Medicines, Inc. Form D, filed Jun 16, 2026
2. SECProgentos Therapeutics, Inc. Form D, filed May 17, 2024